Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 168

Results For "AI"

10419 News Found

Pantherna acquisition to boost T-CURX’s clinical translation of non-viral In Vivo CAR-T strategies
Healthcare | June 01, 2026

Pantherna acquisition to boost T-CURX’s clinical translation of non-viral In Vivo CAR-T strategies

Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier


Ardena appoints Ariane de Ganck as Chief Scientific Officer
People | June 01, 2026

Ardena appoints Ariane de Ganck as Chief Scientific Officer

Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022


Indoco's formulation plant at Baddi receives EU GMP certification
News | June 01, 2026

Indoco's formulation plant at Baddi receives EU GMP certification

This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive


Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
R&D | May 31, 2026

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease


AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
Clinical Trials | May 31, 2026

AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia

The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,


FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough
R&D | May 30, 2026

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term


Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial
Clinical Trials | May 30, 2026

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer


Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting
Drug Approval | May 30, 2026

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial


AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial
Clinical Trials | May 30, 2026

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis